New weapon tested in fight against Tough-to-Treat cancers

NCT ID NCT06819735

Summary

This study is testing a new drug called DT-7012 for people with advanced solid tumors that have spread or returned after other treatments. The main goals are to find a safe dose and see if the drug, given alone or with an immunotherapy, can help control the cancer. It is an early-stage trial for adults whose cancer has progressed and who have no other curative options.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cabrini Health Limited

    RECRUITING

    Malvern, Victoria, 3144, Australia

  • Cancer Research SA

    RECRUITING

    Adelaide, South Australia, 5000, Australia

  • Hôpitaux Universitaires de Strasbourg

    RECRUITING

    Strasbourg, 67200, France

  • Institut Bergonié

    NOT_YET_RECRUITING

    Bordeaux, 33076, France

  • Institut Gustave Roussy

    RECRUITING

    Villejuif, 94800, France

  • Macquarie University Clinical Trial Unit

    RECRUITING

    North Ryde, New South Wales, 2109, Australia

  • One Clinical Research Pty Ltd

    RECRUITING

    Nedlands, Western Australia, 6009, Australia

  • Peninsula & South Eastern Haematology & Oncology Group

    RECRUITING

    Frankston, Victoria, 3199, Australia

Conditions

Explore the condition pages connected to this study.